A securities class action has been filed in the USDC — S.D.N.Y. against Inspire Medical Systems, Inc. (INSP) (“Inspire” or the “Company”) on behalf of all persons and entities that purchased or otherwise acquired the publicly traded common stock of Inspire between August 6, 2024, and August 4, 2025, both dates inclusive (the “Class Period”).

Inspire is a medical device company that develops and markets the “Inspire” system, an implantable neurostimulation system to treat obstructive sleep apnea. The most recent model of the Company’s device, the “Inspire V,” was scheduled to launch in 2025.

The Complaint alleges that throughout the Class Period, Defendants told investors that Inspire would be able to launch the Inspire V as soon as it had built up sufficient levels of inventory and reassured investors that the Company would be “ready to go” in regards to physician training, reimbursement, and contracting in order to facilitate the launch. Once the Company had started the soft launch of Inspire V, it continued to assure investors that it was receiving “tremendous” feedback and that it was “ready to throw the switch and be able to move into full launch.” As the Company progressed to the full launch it represented to investors that it was “making very good progress” in transitioning from the previous generation to Inspire V and that “[i]t’s a pretty straightforward process to transition centers to be able to take on Inspire V and centers are excited to do so.”

Defendants’ Class Period representations that the Company was prepared for the Inspire V launch and that the launch was progressing well were false. In truth, Defendants knew that the Company was facing several critical issues with the Inspire V launch, including lack of demand and problems with reimbursement codes, and getting treatment centers to complete training and install the prerequisite IT program, SleepSync.

The price of Inspire common stock declined more than 32%, from a closing price of $129.95 per share on August 4, 2025, to a closing price of $87.91 per share on August 5, 2025.

If you purchased Inspire common stock during the class period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.